Regeneron Pharmaceuticals
REGN
933 hedge funds and large institutions have $57.9B invested in Regeneron Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 198 funds opening new positions, 387 increasing their positions, 241 reducing their positions, and 74 closing their positions.
168% more first-time investments, than exits
New positions opened: 198 | Existing positions closed: 74
61% more repeat investments, than reductions
Existing positions increased: 387 | Existing positions reduced: 241
57% more capital invested
Capital invested by funds: $36.9B → $57.9B (+$21B)
14% more funds holding
Funds holding: 816 → 933 (+117)
13.85% more ownership
Funds ownership: 70.04% → 83.88% (+14%)
14% more funds holding in top 10
Funds holding in top 10: 22 → 25 (+3)
1% less call options, than puts
Call options by funds: $1.08B | Put options by funds: $1.08B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.27B |
| 2 |
BlackRock
New York
|
+$1.81B |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$912M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$812M |
| 5 |
State Street
Boston,
Massachusetts
|
+$530M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Harris Associates
Chicago,
Illinois
|
-$619M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$160M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$132M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$112M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$109M |
REGN Hedge Fund Activity: Q2 2020 in Review
933 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2020, worth a combined $57.9B — up 57% from $36.9B a quarter earlier.
Buyers outnumbered sellers: 198 funds opened new REGN positions and 74 closed out — a net gain of 124 holders — while 387 added to existing stakes and 241 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.27B. The largest seller was Harris Associates, cutting an estimated $619M.
- 933 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2020, up from 816 in Q1 2020.
- Funds reported $57.9B of Regeneron Pharmaceuticals stock for Q2 2020, up 57% quarter-over-quarter.
- 198 funds opened new Regeneron Pharmaceuticals positions in Q2 2020 and 74 closed out, a net change of +124 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2020 was Fidelity Investments, an estimated $2.27B added.
- The largest Regeneron Pharmaceuticals seller in Q2 2020 was Harris Associates, an estimated $619M sold.
Based on aggregated 13F filings for Q2 2020.